Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000225)
SBP Name
Avimer AMG220
Synonyms
AMG-220; C326; C-326
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I; Discontinued
Protein Scaffold Information of This SBP
Scaffold ID PS014
Scaffold Info
[1] , [2] , [3]
Scaffold Name Avimer
Scaffold Class Non-Antibody
Fold Type (Ca2+) + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Interleukin-6
BTS Info
Inhibitor Crohn disease [ICD-11: DD70] Kd: <0.2 nM Avidia; Amgen [1] , [2] , [3]
Clinical Trial Information of This SBP
NCT00353756 Click to show the Detail
Indication Crohn Disease
Phase Phase I
Title A Placebo-Controlled, Phase I, Single and Multiple IV Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn's Disease
Status Unknown
Sponsor Avidia
References
1 In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018 Jan;9(1):3-14.
2 Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
3 Mult ivalent avimer proteins evolved by exon shuffling of a family of human receptor. Nat Biotechnol. 2005 Dec;23(12):1556-61.